中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 62-69

Guideline on the management of cholestasis liver diseases(2021)

DOI: 10.3760/cma.j.cn112138-20211112-00795
  • Received Date: 2021-12-25
  • Published Date: 2022-01-20
    Abstract
  • In 2015, the Chinese Society of Hepatology and Chinese Society of Gastroenterology issued the consensus on the diagnosis and management of cholestatic liver diseases. In the past years, more data have emerged from clinical practice. Herein, the Autoimmune Liver Disease Group of the Chinese Society of Hepatology organized an expert group to review the evidence and updated the recommendations to formulate the guidelines. There are 22 recommendations on clinical practice of cholestatic liver diseases. The guidelines aim to provide a working reference for the management of cholestatic liver diseases.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    KUNTZ K, KUNTZ HD. Cholestasi hepatology: Principles and practice (2nd edition)[M]. Heidelberg, Germany: Springer Medizin Verlag Heidelberg, 2006: 227-242.
    [2]
    WU H, CHEN C, ZIANI S, et al. Fibrotic events in the progression of cholestatic liver disease[J]. Cells, 2021, 10(5): 1107. DOI: 10.3390/cells10051107.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of cholestasis liver diseases (2015) [J]. J Clin Hepatol, 2015, 31(12): 1989-1999. DOI: 10.3969/j.issn.1001-5256.2015.12.005.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015) [J]. 临床肝胆病杂志, 2015, 31(12): 1989-1999. DOI: 10.3969/j.issn.1001-5256.2015.12.005.
    [4]
    SHERLOCK S, DOOLEY J. Cholestasis[M]//SHERLOCK S, DOOLEY J. Disease of the liver and biliary system. 11th ed. Oxford, England: Blackwell Publishing, 2002: 219-240.
    [5]
    European Association for the Study of the Liver. EASL clinical practice guidelines: Management of cholestatic liver diseases[J]. J Hepatol, 2009, 51(2): 237-267. DOI: 10.1016/j.jhep.2009.04.009.
    [6]
    BURT A, PORTMANN B, FERRELL L. MacSween's pathology of the liver (6th edition)[M]. London, England: Churchill Livingstone Elsevier, 2012: 503-562.
    [7]
    LEFKOWITCH JH. Scheuer's liver biopsy interpretation (9th edition)[M]. New York: Elsevier, 2016: 53.
    [8]
    HILSCHER MB, KAMATH PS, EATON JE. Cholestatic liver diseases: A primer for generalists and subspecialists[J]. Mayo Clin Proc, 2020, 95(10): 2263-2279. DOI: 10.1016/j.mayocp.2020.01.015.
    [9]
    BORTOLINI M, ALMASIO P, BRAY G, et al. Multicentre survey of the prevalence of intrahepatic cholestasis in 2520 consecutive patients with newly diagnosed chronic liver disease[J]. Drug Investigation, 1992, 4(Suppl 4): 83-89.
    [10]
    XIE W, CAO Y, XU M, et al. Prognostic significance of elevated cholestatic enzymes for fibrosis and hepatocellular carcinoma in hospital discharged chronic viral hepatitis patients[J]. Sci Rep, 2017, 7(1): 10289. DOI: 10.1038/s41598-017-11111-5.
    [11]
    CAO XX, GAO YQ, ZHANG WH, et al. Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai[J]. Chin J Hepatol, 2015, 23(8): 569-573. DOI: 10.3760/cma.j.issn.1007-3418.2015.08.003.

    曹旬旬, 高月求, 张文宏, 等. 基于上海市住院慢性肝病患者胆汁淤积患病率的调查研究[J]. 中华肝脏病杂志, 2015, 23(8): 569-573. DOI: 10.3760/cma.j.issn.1007-3418.2015.08.003.
    [12]
    SIDDIQUE A, KOWDLEY KV. Approach to a patient with elevated serum alkaline phosphatase[J]. Clin Liver Dis, 2012, 16(2): 199-229. DOI: 10.1016/j.cld.2012.03.012.
    [13]
    REICHERT MC, HALL RA, KRAWCZYK M, et al. Genetic determinants of cholangiopathies: Molecular and systems genetics[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1484-1490. DOI: 10.1016/j.bbadis.2017.07.029.
    [14]
    VITALE G, GITTO S, VUKOTIC R, et al. Familial intrahepatic cholestasis: New and wide perspectives[J]. Dig Liver Dis, 2019, 51(7): 922-933. DOI: 10.1016/j.dld.2019.04.013.
    [15]
    PIETERS A, GIJBELS E, COGLIATI B, et al. Biomarkers of cholestasis[J]. Biomark Med, 2021, 15(6): 437-454. DOI: 10.2217/bmm-2020-0691.
    [16]
    GELLER S, PETOVIC LM. Evaluation of cholestasis//Biopsy interpretation of the liver (2nd edition)[M]. Philadelphia, USA: Lippincott Williams & Wilkins, 2009: 404-416.
    [17]
    PAUMGARTNER G, BEUERS U. Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited[J]. Hepatology, 2002, 36(3): 525-531. DOI: 10.1053/jhep.2002.36088.
    [18]
    APPANNA G, KALLIS Y. An update on the management of cholestatic liver diseases[J]. Clin Med (Lond), 2020, 20(5): 513-516. DOI: 10.7861/clinmed.2020-0697.
    [19]
    WAGNER M, FICKERT P. Drug therapies for chronic cholestatic liver diseases[J]. Annu Rev Pharmacol Toxicol, 2020, 60: 503-527. DOI: 10.1146/annurev-pharmtox-010818-021059.
    [20]
    FABRIS L, FIOROTTO R, SPIRLI C, et al. Pathobiology of inherited biliary diseases: A roadmap to understand acquired liver diseases[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(8): 497-511. DOI: 10.1038/s41575-019-0156-4.
    [21]
    STAUFER K. Current treatment options for cystic fibrosis-related liver disease[J]. Int J Mol Sci, 2020, 21(22): 8586. DOI: 10.3390/ijms21228586.
    [22]
    BOЁLLE PY, DEBRAY D, GUILLOT L, et al. Cystic fibrosis liver disease: Outcomes and risk factors in a large cohort of French patients[J]. Hepatology, 2019, 69(4): 1648-1656. DOI: 10.1002/hep.30148.
    [23]
    LI LT, LI ZD, YANG Y, et al. ABCB11 deficiency presenting as transient neonatal cholestasis: Correlation with genotypes and BSEP expression[J]. Liver Int, 2020, 40(11): 2788-2796. DOI: 10.1111/liv.14642.
    [24]
    LI L, DEHERAGODA M, LU Y, et al. Hypothyroidism associated with ATP8B1 deficiency[J]. J Pediatr, 2015, 167(6): 1334-1339. e1. DOI: 10.1016/j.jpeds.2015.08.037.
    [25]
    LI LT, LI ZD, YANG Y, et al. ABCB11 deficiency presenting as transient neonatal cholestasis: Correlation with genotypes and BSEP expression[J]. Liver Int, 2020, 40(11): 2788-2796. DOI: 10.1111/liv.14642.
    [26]
    van WESSEL D, THOMPSON RJ, GONZALES E, et al. Genotype correlates with the natural history of severe bile salt export pump deficiency[J]. J Hepatol, 2020, 73(1): 84-93. DOI: 10.1016/j.jhep.2020.02.007.
    [27]
    ZHANG J, LIU LL, GONG JY, et al. TJP2 hepatobiliary disorders: Novel variants and clinical diversity[J]. Hum Mutat, 2020, 41(2): 502-511. DOI: 10.1002/humu.23947.
    [28]
    QIU YL, GONG JY, FENG JY, et al. Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis[J]. Hepatology, 2017, 65(5): 1655-1669. DOI: 10.1002/hep.29020.
    [29]
    ZHANG J, YANG Y, GONG JY, et al. Low-GGT intrahepatic cholestasis associated with biallelic USP53 variants: Clinical, histological and ultrastructural characterization[J]. Liver Int, 2020, 40(5): 1142-1150. DOI: 10.1111/liv.14422.
    [30]
    PAN Q, LUO G, QU J, et al. A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis[J]. EMBO Mol Med, 2021, 13(11): e14563. DOI: 10.15252/emmm.202114563.
    [31]
    GONZALES E, HARDIKAR W, STORMON M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): A randomised phase 2 study[J]. Lancet, 2021, 398(10311): 1581-1592. DOI: 10.1016/S0140-6736(21)01256-3.
    [32]
    EMERICK KM, RAND EB, GOLDMUNTZ E, et al. Features of Alagille syndrome in 92 patients: Frequency and relation to prognosis[J]. Hepatology, 1999, 29(3): 822-829. DOI: 10.1002/hep.510290331.
    [33]
    SHNEIDER BL, SPINO C, KAMATH BM, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome[J]. Hepatol Commun, 2018, 2(10): 1184-1198. DOI: 10.1002/hep4.1244.
    [34]
    FLOREANI A, GERVASI MT. New insights on intrahepatic cholestasis of pregnancy[J]. Clin Liver Dis, 2016, 20(1): 177-189. DOI: 10.1016/j.cld.2015.08.010.
    [35]
    WOOD AM, LIVINGSTON EG, HUGHES BL, et al. Intrahepatic cholestasis of pregnancy: A review of diagnosis and management[J]. Obstet Gynecol Surv, 2018, 73(2): 103-109. DOI: 10.1097/OGX.0000000000000524.
    [36]
    SMITH DD, ROOD KM. Intrahepatic cholestasis of pregnancy[J]. Clin Obstet Gynecol, 2020, 63(1): 134-151. DOI: 10.1097/GRF.0000000000000495.
    [37]
    LANGEDIJK J, BEUERS UH, OUDE ELFERINK R. Cholestasis-associated pruritus and its pruritogens[J]. Front Med (Lausanne), 2021, 8: 639674. DOI: 10.3389/fmed.2021.639674.
    [38]
    PATEL SP, VASAVDA C, HO B, et al. Cholestatic pruritus: Emerging mechanisms and therapeutics[J]. J Am Acad Dermatol, 2019, 81(6): 1371-1378. DOI: 10.1016/j.jaad.2019.04.035.
    [39]
    BERGASA NV, JONES EA. Assessment of the visual analogue score in the evaluation of the pruritus of cholestasis[J]. J Clin Transl Hepatol, 2017, 5(3): 203-207. DOI: 10.14218/JCTH.2017.00001.
    [40]
    THÉBAUT A, HABES D, GOTTRAND F, et al. Sertraline as an additional treatment for cholestatic pruritus in children[J]. J Pediatr Gastroenterol Nutr, 2017, 64(3): 431-435. DOI: 10.1097/MPG.0000000000001385.
    [41]
    WEBB GJ, RAHMAN SR, LEVY C, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: A cross-disease cohort study[J]. Aliment Pharmacol Ther, 2018, 47(8): 1213-1219. DOI: 10.1111/apt.14579.
    [42]
    PHAW NA, LEIGHTON J, DYSON JK, et al. Managing cognitive symptoms and fatigue in cholestatic liver disease[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(3): 235-241. DOI: 10.1080/17474124.2021.1844565.
    [43]
    SWAIN MG, JONES D. Fatigue in chronic liver disease: New insights and therapeutic approaches[J]. Liver Int, 2019, 39(1): 6-19. DOI: 10.1111/liv.13919.
    [44]
    DUBROVSKY A, BOWLUS CL. Statins, fibrates, and other peroxisome proliferator-activated receptor agonists for the treatment of cholestatic liver diseases[J]. Gastroenterol Hepatol (N Y), 2020, 16(1): 31-38.
    [45]
    European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2688) PDF downloads(1315) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return